Influvac Sub-Unit Tetra

B/Phuket/3073/2013-like virus (B/Phuket/3073/2013, Wild Type) and Influenza Virus B/Austria/1359417/202, the active ingredients in Influvac Sub-Unit Tetra, is a vaccine presented as an injectable solution for intramuscular or subcutaneous use. It is intended to induce immunity that helps prevent influenza B infection in individuals at risk, including children and adults. GNH USA supplies Influvac Sub-Unit Tetra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Influvac Sub-Unit Tetra is a subunit influenza vaccine used to protect against influenza virus infections, primarily targeting the B lineage. - Influenza B infection: reduces the risk of laboratory‑confirmed influenza B disease. - Seasonal influenza (A and B strains): contributes to overall seasonal flu prevention when administered as part of a tetravalent formulation. - High‑risk populations (elderly, chronic disease patients, pregnant women): provides added protection to groups more likely to experience severe flu complications.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling: localized erythema or edema. - Low‑grade fever: transient temperature rise within 24‑48 hours. - Headache: mild headache following vaccination. - Myalgia: muscle aches that resolve spontaneously. - Fatigue: temporary tiredness after immunisation.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurological disorder potentially linked to vaccination. - Seizures: infrequent occurrence, especially in children with a history of febrile seizures. - Severe local reaction: extensive swelling or necrosis at the injection site. - Thrombotic events: extremely rare clotting complications. - Acute respiratory distress: rare severe respiratory compromise.

Before administering Influvac Sub-Unit Tetra, consider the following precautions: - Allergy assessment: avoid in individuals with known severe allergy to any vaccine component. - Acute illness: defer vaccination in persons with moderate or severe febrile illness. - Immunocompromised patients: evaluate risk‑benefit, as response may be reduced. - Pregnancy and lactation: discuss potential benefits and unknown risks with a healthcare professional. - Concomitant vaccines: follow recommended intervals when co‑administering other vaccines. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vaccines may interact with other agents that modify the immune response. Major Interactions (Avoid): - Concurrent administration of another influenza vaccine: may increase reactogenicity. - High‑dose immunoglobulin therapy within 3 weeks: can diminish vaccine efficacy. Moderate Interactions (Monitor Closely): - Antipyretics (e.g., acetaminophen, ibuprofen) taken prophylactically: may slightly reduce antibody response. - Systemic corticosteroids: may blunt immunogenicity if used at high doses. - Live attenuated vaccines given within 4 weeks: monitor for overlapping adverse events.